Press releases 2022

ADDvise Group AB’s subsidiary Poly Pharmaceuticals Inc has received an additional order from Cochran Wholesale Pharmaceuticals, a generic pharmaceutical wholesale distributor serving the needs of independent pharmacies across the USA. The order is worth approximately USD 1.2 million. The order consists of delivery of the dietary supplemental Folite, developed and manufactured by Poly Pharmaceuticals. Delivery…

Fredrik Mella has today been appointed Senior Vice President of ADDvise alongside his current role as Chief Operating Officer (COO). Fredrik Mella has worked as COO at ADDvise since February 2022. As COO, Fredrik has an overall responsibility for ensuring that the companies within the group are reaching ADDvise’s organic financial targets. He is now…

ADDvise Group AB’s subsidiary Poly Pharmaceuticals Inc has received an order from Wellgistics, a pharmaceutical wholesale distributor delivering to independent pharmacies in USA. The order is worth approximately USD 1.5 million. The order consists of delivery of the dietary supplemental Folite, developed and manufactured by Poly Pharmaceuticals. Delivery will take place immediately. For further information,…

ADDvise Group AB’s subsidiary Poly Pharmaceuticals Inc has received an order from Cochran Wholesale Pharmaceuticals, a generic pharmaceutical wholesale distributor serving the needs of independent pharmacies across the USA. The order is worth approximately USD 2.1 million. The order regards delivery of Folite, a folic acid dietary supplemental developed and manufactured by Poly Pharmaceuticals. Delivery…

ADDvise Group AB (publ) (the "Company") today announces the successful completion of the written procedure that was initiated on 21 November 2022 (the "Written Procedure") in relation to the Company's outstanding senior secured bonds with ISIN SE0015222088 (the "Bonds"), seeking approval from bondholders for certain amendments to the terms and conditions of the Bonds (the…

ADDvise Group AB has today entered into a share purchase agreement with the owners of CliniChain Holding B.V. (“CliniChain”) regarding the acquisition of all the outstanding shares of CliniChain in accordance with the letter of intent communicated via a press release dated September 6, 2022. Closing of the acquisition takes place no later than December…

ADDvise Group AB’s subsidiary MRC Systems FZE has received an order from BioGeneric Pharma, a leading factory in biotechnology based in Cairo, Egypt. The order is worth approximately USD 1.7 million. The order is an add-on-project in the ongoing project between the parties regarding design, supply, and commissioning of clean room environment to be used…

ADDvise Group AB (publ) ("ADDvise" or the "Company") announces today that the Company has successfully placed a subsequent senior secured bond issue (the “Subsequent Bond Issue") in an amount of SEK 150 million under the Company’s existing senior secured bond framework with ISIN SE0015222088. Following completion of the Subsequent Bond Issue, the outstanding amount under…

ADDvise Group AB (publ) (the "Company" and together with its subsidiaries from time to time, the "Group") has instructed the agent for the Company's senior secured bonds with ISIN SE0015222088 (the "Bonds") to initiate a written procedure to request that bondholders vote in favour of inter alia (i) increasing the framework from SEK 500 million…

ADDvise Group AB (publ) has mandated Pareto Securities AB to arrange a series of fixed income investor meetings starting on 22 November 2022. Subject to inter alia market conditions, a subsequent bond issue of SEK 150 million under the company's existing senior secured bond loan with ISIN SE0015222088 (the "Bonds") may follow. The subsequent bond…

July-September 2022 Net revenue for the period was SEK 237.0 million (105.6), an increase of 124.5 %. Organic growth was 27.2 %. Orders received for the period was SEK 268.4 million (107.1), an increase of 150.7 %. Organic growth was 20.6 %. Adjusted EBITDA for the period was SEK 36.0 million (14.5) EBITDA for the…

In accordance with the resolution at the 2022 annual general meeting of ADDvise Group, the nomination committee for the annual general meeting 2023 shall compose of representatives of the three largest shareholders by votes, according to the shareholders’ register maintained by Euroclear Sweden as of 30 June 2022, and the chairman of the board of…

ADDvise Group AB (publ) has signed a Letter of Intent with the shareholders of CliniChain Holding B.V. (”CliniChain”) regarding an acquisition of 100 percent of the shares in CliniChain. CliniChain is a fast-growing international medtech equipment provider for clinical studies. The company offers tailored rental and purchase solutions of medtech equipment that are adapted to…

ADDvise Group AB’s subsidiary MRC Systems FZE has received an order from Hortman Health Care Investment LLC, an investment company in the private healthcare sector, based in the United Arab Emirates. The order is worth approximately USD 640,000 and involves design, supply, and installation of a stem cell laboratory for a clinic in Dubai, United…

April-June 2022 Orders received for the period was SEK 260.9 million (122.8), an increase of 112.5 %. Organic growth was 22.3 %. Net revenue for the period was SEK 231.9 million (117.6), an increase of 97.1 %. Organic growth was 3.1 %. Adjusted EBITDA for the period was SEK 31.8 million (15.5) EBITDA for the…

ADDvise Group AB (publ)’s subsidiary Sonar Oy has received an allocation decision from Helsinki University Hospital in Finland regarding digital x-ray equipment with a total value of approximately EUR 2.4 million. Installations are expected to take place during the year 2022 and 2023. In accordance with Finnish procurement law the allocation decision can be appealed…

ADDvise Group AB’s subsidiary Merit Cables Inc has received an order from Cadwell Industries, a company specialized in electrodes, consumables, supplies, and accessories for neurology, worth approximately USD 1.7 million. The order involves wires for electrodiagnostic supplies such as EEG, EMG and ultrasound for measuring and evaluating electrical brain and muscle activity. Delivery of the…

ADDvise Group AB has today entered into a share purchase agreement with the owners of Seebreath AB (“Seebreath”) regarding the acquisition of all the outstanding shares of Seebreath. The acquisition is in line with the letter of intent communicated via a press release dated February 28, 2022. Closing of the acquisition takes place today. Seebreath’s…

ADDvise Group AB (publ), reg. no. 556363–2115, has held its annual general meeting on May 6, 2022 at 10.00 a.m. at Grev Turegatan 30 in Stockholm. At the meeting, the following resolutions were, amongst others, adopted.

January-March 2022 Net revenue for the period was SEK 162.4 million (87.7), an increase of 85.1 %. Organic growth was 4.2 %. Adjusted EBITDA for the period was SEK 21.3 million (8.0) EBITDA for the period was SEK 21.2 million (8.9) Adjusted profit/loss for the period was SEK 5.8 million (1.6) Basic earnings per share…

ADDvise Group AB has today entered into a share purchase agreement with the owners of Surplus Diabetics, Inc. (“Surplus Diabetics”) regarding the acquisition of all the outstanding shares of Surplus Diabetics in accordance with the letter of intent communicated via a press release dated January 17, 2022. Closing of the acquisition takes place today. Surplus…

Today, April 14, 2022, ADDvise Group AB (publ) is publishing its annual report for 2021. The annual report is available on ADDvise’s website: www.addvisegroup.se. The annual report is published in Swedish and English. The Swedish version represents the original. For further information, please contact: Rikard Akhtarzand, CEO +46765-25 90 71 rikard.akhtarzand@addvisegroup.se Sebastian Robson, CFO +46…

In the light of the company’s continued progress, the Board of Directors of ADDvise Group have decided to raise the 2022 EBITDA target from the previous target communicated on 23 September 2021. For the financial year 2022, rolling 12 months pro forma basis, ADDvise expects to reach an EBITDA result of at least SEK 200…

ADDvise Group AB (publ), reg. no. 556363–2115 (the "Company" and "ADDvise"), hereby convenes the annual general meeting to be held on Friday 6 May 2022 at 10.00 a.m. at Grev Turegatan 30 in Stockholm. Registration for the meeting will begin at 09.30 a.m. Registration and notification Shareholders wishing to attend the annual general meeting must:…

ADDvise Group AB’s subsidiary Southern Life Systems Inc (“SLS”) has signed a one-year term agreement with Signature Healthcare Consulting Services, LLC (“SHCS”), a group providing personalized medical services in primary care, specialty care and hospital care. The agreement regards an order of Rosie Connectivity Solution, system for vital signs monitoring, in 110 nursing homes in…

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, NEW ZEALAND, HONG KONG, JAPAN, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. PLEASE REFER…

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, NEW ZEALAND, HONG KONG, JAPAN, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. PLEASE REFER…

ADDvise Group AB (publ)’s subsidiary Hettich Labinstrument AB has received an allocation decision from Region Stockholm-Gotland worth approximately SEK 44 million. The allocation decision consists of delivery of blood specimen collection equipment during a four-year period starting May 2022. The allocation decision is subject to an appeal time expiring 18 March 2022. For further information,…

ADDvise Group AB has today entered into a share purchase agreement with the owner of JTECH Medical (“JTECH”) regarding the acquisition of all shares of the company in accordance with the letter of intent communicated via a press release dated December 22, 2021. Closing of the acquisition takes place today. JTECH’s revenue for 2021 amounted…

ADDvise signs Letter of Intent to acquire Seebreath AB ADDvise Group AB (publ) has signed a Letter of Intent with the shareholders of Seebreath AB (”Seebreath”) regarding an acquisition of 100 percent of the shares in Seebreath. Seebreath is a Swedish medtech company developing and producing colorimetric CO2-indicating products used in respiratory care. The products are…

October – December 2021 Net revenue for the period was SEK 155.0 million (96.8), an increase of 60.1 %. Organic growth was 12.8 %. Adjusted EBITDA for the period was SEK 19.0 million (12.6) EBITDA for the period was SEK 19.4 million (16.3) Adjusted profit/loss for the period was SEK 3.8 million (2.4) Basic earnings…

ADDvise Group AB has today entered into a share purchase agreement with the shareholders of Poly Pharmaceuticals, Inc. (“Poly Pharma”) regarding the acquisition of all the outstanding shares of Poly Pharma in accordance with the letter of intent communicated via a press release dated October 21, 2021. Closing of the acquisition will take place during…

To the annual general Meeting (AGM) of ADDvise Group AB (publ) on 6 May 2022, the nomination committee has decided to propose re-election of Fredrik Celsing, Staffan Torstensson, Erland Pontusson and Johanne Brændgaard as members of the board of directors. In addition, the nomination committee proposes the election of Anna Ljung. It is proposed that…

ADDvise Group AB (publ) has signed a Letter of Intent with the shareholders of Surplus Diabetic, Inc. (”Surplus Diabetic”) regarding an acquisition of 100 percent of the shares in Surplus Diabetic. Surplus Diabetic is an American medtech company, specialized in supplying the U.S. market with diabetes products, such as glucose monitors, insulin and test stripes.…

ADDvise Group AB (publ) (the "Company") today announces the successful completion of the written procedure that was initiated on 16 December 2021 (the "Written Procedure") in relation to the Company's outstanding up to SEK 500,000,000 senior secured bonds with ISIN SE0015222088 (the "Bonds"), that sought approval from bondholders ("Bondholders") for certain amendments to the terms…

The board of directors of ADDvise Group AB has today been informed that one of its major shareholders, Per Åhlgren through GoMobile nu Aktiebolag, has issued call options in ADDvise Group AB to board members, senior executives and certain other employees in ADDvise Group. In total, 3,696,666 call options have been issued to eleven persons.…

ADDvise Group AB’s subsidiary MRC Systems FZE has received an order from Design Infinity LCC, a Dubai based pharmaceutical industry engineering, interior design and fit out contractor. The order is worth approximately USD 1.1 million and involves design, supply, and installation of a 1000 sqm cleanroom facility for pharmaceutical production by the Himalaya Drug Company…